We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+36.02%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$334M
AUM Growth
+$107M
Cap. Flow
+$48M
Cap. Flow %
14.36%
Top 10 Hldgs %
34.01%
Holding
80
New
29
Increased
13
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
LHCG
LHC Group LLC
LHCG
+$11M
2
CRL icon
Charles River Laboratories
CRL
+$8.78M
3
COR icon
Cencora
COR
+$8.29M
4
NUVA
NuVasive, Inc.
NUVA
+$7.23M
5
MOH icon
Molina Healthcare
MOH
+$6.81M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$10.4M
2
CNC icon
Centene
CNC
+$10.1M
3
EHC icon
Encompass Health
EHC
+$7.36M
4
MASI
Masimo
MASI
+$6.2M
5
NVS icon
Novartis
NVS
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 86.88%
2 Energy 6.53%
3 Technology 0.84%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LHCG
1
DELISTED
LHC Group LLC
LHCG
$21.8M 6.53%
125,000
+75,000
+150% +$11M
DGX icon
2
Quest Diagnostics
DGX
$25.6B
$13.7M 4.1%
120,000
– –
BMY icon
3
Bristol-Myers Squibb
BMY
$134B
$11.8M 3.52%
200,000
+25,000
+14% +$1.5M
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11M 3.3%
175,000
+65,000
+59% +$3.58M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.6B
$9.87M 2.95%
80,000
-30,000
-27% -$2.98M
CRL icon
6
Charles River Laboratories
CRL
$11.1B
$9.59M 2.87%
+55,000
New +$8.78M
GWPH
7
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.2M 2.76%
75,000
– –
COR icon
8
Cencora
COR
$60B
$9.07M 2.72%
+90,000
New +$8.29M
NVRO
9
DELISTED
NEVRO CORP.
NVRO
$8.96M 2.68%
75,000
+35,000
+88% +$4.15M
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
$8.63M 2.58%
150,000
-40,000
-21% -$2.18M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
$8.58M 2.57%
110,000
+50,000
+83% +$3.38M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$8.11M 2.43%
195,000
+25,000
+15% +$907K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$1.82B
$8.02M 2.4%
150,000
– –
CYTK icon
14
Cytokinetics
CYTK
$10.4B
$8.01M 2.4%
340,000
+20,000
+6% +$375K
DHR icon
15
Danaher
DHR
$139B
$7.96M 2.38%
50,760
-5,640
-10% -$809K
HUM icon
16
Humana
HUM
$45B
$7.75M 2.32%
20,000
+15,000
+300% +$5.61M
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$7.65M 2.29%
+45,000
New +$6.71M
REGN icon
18
Regeneron Pharmaceuticals
REGN
$78.2B
$7.48M 2.24%
+12,000
New +$6.81M
CTLT
19
DELISTED
CATALENT, INC.
CTLT
$7.33M 2.2%
100,000
-50,000
-33% -$3.39M
MOH icon
20
Molina Healthcare
MOH
$10.2B
$7.12M 2.13%
+40,000
New +$6.81M
NUVA
21
DELISTED
NuVasive, Inc.
NUVA
$6.96M 2.08%
+125,000
New +$7.23M
AZN icon
22
AstraZeneca
AZN
$245B
$6.61M 1.98%
62,500
-32,500
-34% -$3.36M
DXCM icon
23
DexCom
DXCM
$32.9B
$6.08M 1.82%
+60,000
New +$5.37M
UHS icon
24
Universal Health Services
UHS
$10.2B
$6.04M 1.81%
+65,000
New +$6.5M
AMGN icon
25
Amgen
AMGN
$204B
$5.9M 1.77%
+25,000
New +$5.7M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Integral Health Asset Management held 80 positions worth $334M, up 47% from $227M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Integral Health Asset Management deployed $48M of net new capital in Q2 2020, opening 29 new positions and adding to 13 existing holdings. Its largest new stake was Charles River Laboratories: 55,000 shares worth $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was Merck, an estimated $4.34M trimmed.

  • Integral Health Asset Management's largest Q2 2020 buy was Charles River Laboratories: 55,000 shares worth $9.59M.
  • Integral Health Asset Management added most to LHC Group LLC in Q2 2020, an estimated $11M increase.
  • Integral Health Asset Management's biggest Q2 2020 reduction was Merck, cutting an estimated $4.34M.
  • Integral Health Asset Management fully exited Medtronic in Q2 2020, selling an estimated $10.4M.
  • Integral Health Asset Management's ten largest holdings make up 34% of its $334M portfolio in Q2 2020.
  • Integral Health Asset Management opened 29 new positions and closed 20 in Q2 2020.
  • Integral Health Asset Management's portfolio value rose 47% quarter-over-quarter to $334M.

Based on Integral Health Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.